Buserelin is a synthetic GnRH super-agonist that, upon sustained administration, downregulates pituitary GnRH receptors and suppresses gonadal hormone production, used in prostate cancer, endometriosis and controlled ovarian stimulation protocols. Simson Pharma's Buserelin reference standard and impurities support QC for this peptide-based hormonal therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Buserelin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.